Related Experiment Video
Updated: May 17, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial
Heather A Pines1, Pamina M Gorbach, Robert E Weiss
1Department of Epidemiology, Fielding School of Public Health, University of California-Los Angeles, 650 Charles E. Young Dr., South CHS 41-295A, P.O. Box 951772, Los Angeles, CA, 90095-1772, USA. hpines@ucla.edu
Abstract:
We assessed the acceptability of three of over-the-counter products representative of potential rectal microbicide (RM) delivery systems. From 2009 to 2010, 117 HIV-uninfected males (79 %) and females (21 %) who engage in receptive anal intercourse participated in a 6-week randomized crossover acceptability trial. Participants received each of three products (enema, lubricant-filled applicator, suppository) every 2 weeks in a randomized sequence. CASI and T-ACASI scales assessed product acceptability via Likert responses. Factor analysis was used to identify underlying factors measured by each scale. Random effects models were fit to examine age and gender effects on product acceptability. Three underlying factors were identified: Satisfaction with Product Use, Sexual Pleasure, and Ease of Product Use. For acceptability, the applicator ranked highest; however, differences between product acceptability scores were greatest among females and younger participants. These findings indicate that RM delivery systems impact their acceptability and should be considered early in RM development to enhance potential use.
Related Concept Videos
Intrauterine Drug Delivery Systems
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Oral Drug Delivery Systems: Continuous-Release Systems

